8-K: Safety Shot Responds to FSD Pharma's Allegations and Confirms National Launch

Safety Shot, Inc. has responded to FSD Pharma's claims, asserting they did not acquire GBB Drink Lab, and are proceeding with the national launch of their beverage.

Summary

• Safety Shot, Inc. has issued a press release addressing claims made by FSD Pharma, clarifying that they did not acquire GBB Drink Lab, but only the Safety Shot beverage asset.
• The company emphasizes that the ongoing lawsuit is between FSD Pharma and GBB, not Safety Shot.
• Safety Shot is moving forward with the national launch of its wellness beverage, which is designed to reduce blood alcohol content and boost clarity.
• The Safety Shot beverage has been available for retail purchase since the first week of December 2023 through their website and Amazon.
• The company plans to expand sales to distributors, retailers, restaurants, and bars in the first quarter of 2024.
• Safety Shot also intends to spin off legacy assets from its Jupiter Wellness business to enhance shareholder value.

Sentiment

Score: 6

Explanation: The document presents a mix of positive developments, such as the product launch and legal progress, and negative aspects, such as the ongoing dispute and FSD Pharma's actions. The overall sentiment is cautiously optimistic.

Positives

• The court's refusal to dismiss GBB's lawsuit against FSD Pharma suggests a favorable legal position for GBB.
• Safety Shot's beverage launch is progressing as planned, with retail sales already underway.
• The company is expanding its sales channels to include business-to-business opportunities in the near future.
• The planned spin-off of legacy assets could unlock additional value for shareholders.

Negatives

• FSD Pharma is allegedly attempting to harm Safety Shot and its shareholders by making false claims and unauthorized tagging of the company's stock ticker.
• The ongoing legal dispute between GBB and FSD Pharma could create uncertainty for Safety Shot, although they are not directly involved in the lawsuit.

Risks

• The company faces risks and uncertainties related to forward-looking statements, including the timing of studies and the results and benefits thereof.
• The legal dispute between GBB and FSD Pharma could have indirect implications for Safety Shot.
• FSD Pharma's actions could negatively impact Safety Shot's stock price and shareholder confidence.

Future Outlook

Safety Shot plans to launch business-to-business sales in the first quarter of 2024 and intends to spin off legacy assets from its Jupiter Wellness business to unlock value for shareholders. The company also acknowledges risks and uncertainties related to forward-looking statements.

Management Comments

• GBB CEO John Gulyas stated that the court's decision not to dismiss GBB's case demonstrates a strong legal position.
• GBB CEO John Gulyas said they look forward to a full and fair proceeding and believe they will be victorious.

Industry Context

This announcement highlights the competitive landscape in the functional beverage market, where companies are actively developing and launching new products. The legal dispute between GBB and FSD Pharma underscores the importance of intellectual property protection and non-disclosure agreements in this industry.

Comparison to Industry Standards

• The functional beverage market is highly competitive, with companies like Celsius Holdings and Bang Energy experiencing rapid growth.
• Safety Shot's focus on reducing blood alcohol content is a unique selling proposition, differentiating it from other wellness beverages.
• The legal dispute with FSD Pharma is not uncommon in the biotech and beverage industries, where intellectual property is highly valued.
• The planned spin-off of legacy assets is a strategy used by companies to focus on core business operations and unlock shareholder value, similar to moves by other companies in the consumer goods sector.

Legal Proceedings

• GBB has an ongoing lawsuit against FSD Pharma for violating a Non-Disclosure Agreement and breaching a contract.
• A federal court has refused to dismiss GBB's lawsuit against FSD Pharma.

Stakeholder Impact

• Shareholders may be impacted by the legal dispute and FSD Pharma's actions.
• The national launch of Safety Shot's beverage could positively impact customers.
• The spin-off of legacy assets could unlock value for shareholders.

Next Steps

• Safety Shot plans to launch business-to-business sales in the first quarter of 2024.
• The company intends to spin off legacy assets from its Jupiter Wellness business.
• GBB will continue its legal proceedings against FSD Pharma.

Key Dates

Keywords

Safety Shot, FSD Pharma, GBB Drink Lab, lawsuit, wellness beverage, national launch, blood alcohol content, spin-off, legal dispute, shareholders